Aortic Valve Insufficiency
MIT’s Boltz-1 AI Model Rivals AlphaFold 3 in Biomolecular Structure Prediction
MIT; Boltz-1; AlphaFold 3; AI model; biomolecular structure prediction; drug discovery; protein folding; open-source AI
Post-Hoc: AI bio needs to heed the overhyped history of CRISPR
CRISPR; AI in biotech; overhype; gene editing; reproductive health biotech
Boehringer Ingelheim Expands Oncology Pipeline via Strategic Collaboration with Tempus AI
Boehringer Ingelheim; Tempus AI; oncology; cancer research; real-world data; AI; biomarker discovery; drug development; strategic collaboration
OpenAI Debuts HealthBench Dataset to Evaluate AI Models in Real-World Medical Scenarios
OpenAI; HealthBench; AI healthcare benchmark; large language models; medical AI evaluation; physician rubrics; realistic medical scenarios; AI safety; open-source dataset
Where AI Adds Real Value in Clinical Development: 2025 Insights
AI in clinical development; clinical trials; drug discovery; protocol design; patient recruitment; data analysis; regulatory compliance
FDA eyes full AI integration by June as Makary touts genAI pilot success
United States Food and Drug Administration, Aortic Valve Insufficiency, DNA Integration, Artificial Intelligence, Makary, June
Lilly backs $65M raise for biotech plumbing the ‘dark genome’ with AI
Haya, Eli Lilly, Genome, Long Intergenic Non-Protein Coding RNA, Obesity, Aortic Valve Insufficiency, Eli, Dark color
AI Drug Discovery Firm Insitro Lays Off 22% of Workforce Amid Ongoing Biotech Market Turmoil
Insitro, AI drug discovery, biotechnology layoffs, workforce reduction, tumultuous market, industry restructuring, biotech market trends, clinic readiness, cost-cutting, 2025 biotech layoffs
Ono Pharmaceutical and Jorna Therapeutics Partner for AI-Driven RNA Editing Therapies
Ono Pharmaceutical, Jorna Therapeutics, AI Drug Discovery, RNA Editing Therapies
PRISM BioLab and Elix Collaborate to Revolutionize AI-Driven Drug Discovery with Peptide Mimetics
PRISM BioLab , Elix , AI drug discovery , Peptide mimetics , Protein-protein interactions , PepMetics® , Small molecule inhibitors , Drug discovery efficiency , Pharmaceutical innovation